The Cannabis Use Disorder Market focuses on therapeutic products and interventions designed to treat individuals struggling with cannabis dependence. Key offerings include pharmacotherapies such as cannabinoid receptor modulators, behavioral therapies, and combination treatment programs that integrate counseling with medication management. These solutions aim to reduce withdrawal symptoms, prevent relapse, and improve patient quality of life. Advantages of available treatments include evidence-based efficacy, targeted delivery mechanisms, and potential for personalized dosing.
The growing need for Cannabis Use Disorder Market is driven by an uptick in cannabis consumption worldwide, increasing recognition of cannabis use disorder as a clinical diagnosis, and a shift toward medicalized approaches over punitive measures. Healthcare providers and payers are seeking cost-effective solutions that can shorten treatment durations and lower readmission rates. Continuous innovation in drug formulations and digital health platforms further enhances patient monitoring and adherence. As market players focus on expanding their product portfolios through robust clinical pipelines and strategic collaborations, stakeholders benefit from comprehensive market research and market insights that guide investment and business growth strategies.
The cannabis use disorder market is estimated to be valued at USD 1.80 Bn in 2025 and is expected to reach USD 3.40 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032.
Key Takeaways
Key players operating in the Cannabis Use Disorder Market are:
-Aelis Farma
-Indivior
-Pfizer
-Corbus Pharmaceuticals
-Zynerba Pharmaceuticals
These market companies lead in R&D investment, leveraging strong pipelines and regulatory approvals to capture market share. Through collaborative agreements, licensing deals, and focused clinical trials, they set benchmarks for safety, efficacy, and commercial launch timelines. Their presence shapes market dynamics and influences competitive pricing strategies across regions.
Significant market opportunities arise from unmet clinical needs and expanding patient pools. The rising incidence of cannabis use disorder in both developed and emerging economies underscores demand for novel pharmacological agents and digital therapeutics. Market research indicates patient preference shifting toward outpatient treatment models and telehealth-enabled care, opening avenues for remote monitoring solutions. Partnerships between biotech firms and digital health providers can unlock new value chains, while formulation improvements—such as extended-release injectables or transdermal patches—enhance adherence and therapeutic outcomes. These market opportunities align with broader industry trends toward personalized medicine and real-world evidence generation.
Global expansion of the Cannabis Use Disorder Market is fueled by regulatory easing and increased healthcare spending in North America, Europe, Asia-Pacific, and Latin America. In North America, reimbursement policies and patient awareness drive adoption, whereas Europe sees growth through harmonized clinical guidelines and government funding for addiction services. Emerging markets in Asia and Latin America present untapped potential as governments revise legislation and invest in mental health infrastructure. Strategic alliances, local manufacturing partnerships, and targeted marketing campaigns enable market players to overcome entry barriers, adapt to regional market segments, and optimize market revenue streams on a global scale.
Market Drivers
Rising Prevalence of Cannabis Use Disorder and Growing Demand for Effective Therapies
One of the primary market drivers for the Cannabis Use Disorder Market is the increasing prevalence of cannabis use disorder across diverse demographic groups, which heightens demand for safe and effective treatment options. Epidemiological studies report a steady uptick in cannabis dependence, particularly among young adults, driven by legalization, social acceptance, and potency increases in cannabis products. This surge elevates the need for specialized pharmacotherapies and behavioral interventions that can address withdrawal management, craving reduction, and relapse prevention. Moreover, healthcare systems and insurers are recognizing the long-term cost savings associated with early intervention and comprehensive treatment plans, prompting policy support and reimbursement frameworks. Ongoing market analysis highlights that governments and public health agencies are allocating funds to substance abuse programs, while private payers explore value-based contracts to improve patient outcomes. Concurrently, pharmaceutical and biotech companies invest heavily in clinical trials to validate novel compounds targeting endocannabinoid receptors, monoclonal antibodies, and neuromodulation techniques. This confluence of rising patient numbers, favorable regulatory environments, and robust R&D activity drives market growth, shaping the competitive landscape and expanding market scope over the forecast period.
PEST Analysis
Political: Governments in major economies are strengthening regulations around cannabis therapeutics to address public health implications of cannabis use disorder, influencing policy frameworks.
Economic: Rising healthcare expenditures and reimbursement policies for addiction treatments shape funding allocations in the cannabis use disorder treatment space.
Social: Growing societal awareness of substance use disorders and destigmatization trends drive patient demand for more effective cannabis use disorder interventions.
Technological: Advances in digital therapeutics and telemedicine platforms are expanding the range of delivery channels for cannabis use disorder treatment. Investments in data analytics and AI are accelerating the development of personalized interventions and improving overall market dynamics.
North America commands a substantial portion of the overall industry size for cannabis use disorder treatments, driven by robust research infrastructure, comprehensive reimbursement frameworks and progressive regulatory approvals. The United States in particular holds a leading market share, bolstered by extensive clinical trials, high awareness among healthcare professionals and a mature pharmaceutical base. Canada contributes significantly to regional revenues, with public health initiatives supporting early diagnosis and management programs. In Europe, markets such as the UK, Germany and France exhibit steady growth in both treatment uptake and R&D investment, reflecting key market trends and collaborative market research efforts. European market insights highlight a growing focus on evidence-based interventions, where harmonized regulations and cross-border collaborations are fueling increased adoption. Within Asia Pacific, advanced economies like Australia are establishing themselves as emerging hubs, although regional market dynamics remain shaped by diverse regulatory environments, local reimbursement models and varying levels of public acceptance.
Asia Pacific represents the fastest growing region for cannabis use disorder treatment, presenting significant market opportunities as regulatory landscapes evolve across countries such as India, South Korea and Japan. Rapidly expanding patient pools, coupled with increasing healthcare budgets and an upsurge in local clinical research initiatives, are key market drivers. Moreover, growing public health concerns related to cannabis misuse are prompting governments to support expanded treatment access and reimbursement schemes. Emerging markets in Latin America and the Middle East also demonstrate promising growth trajectories, with policy reforms, improved healthcare infrastructure and rising disease awareness contributing to accelerating adoption rates. Market challenges such as regulatory inconsistency, limited treatment awareness in certain developing economies and fragmented distribution networks underscore the need for targeted educational programs, partnership models and robust market analysis. Robust market growth strategies centered on localized insights, stakeholder engagement and flexible distribution networks are critical to capturing value in these high-potential regions.
‣ Get this Report in Japanese Language: 大麻使用障害市場
‣ Get this Report in Korean Language: 대마사용장애시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)